DEVELOPMENT OF FOUR UV-SPECTROMETRIC TECHNIQUES FOR CONCURRENT ESTIMATION OF ASPIRIN AND SILDENAFIL CITRATE IN THEIR BINARY MIXTURE AND PHARMACEUTICAL FORMULATIONS

Amir Alhaj Sakur* and Zahraa Kayali

Analytical and Food Chemistry Department, Faculty of Pharmacy, University of Aleppo, Aleppo, Syria

The combination of aspirin (ASP) and sildenafil citrate (SIL) into single dosage form has been of interest for a considerable period; because it has a synergistic effect for the handling of many diseases. Therefore, UV-spectrometric techniques were desperately required for the concurrent estimation of ASP and SIL in their binary mixture and pharmaceutical formulations. In this paper, four simple, low-cost and precise UV-spectrometric techniques were evolved for the concurrent estimation of ASP and SIL. The advanced methods include treatment of the zero-order spectrum by ratio subtraction (RS) along with spectrum subtraction method (SS), absorption correction method (ACM), area under the curve correction method (AUCCM) and induced dual wavelength method (IDWM). Moreover, UV-spectrometric purity analysis via spectral ratio factor (SRF) was developed; which considered the first UV-spectrometric purity testing to verify the purity of ASP in pharmaceuticals formulations.

All approaches were linear; in the range of 25.0-100.0 μg/mL for ASP, and 10.0-50.0 μg/mL for SIL. The mean percentage recoveries for ASP were 100.92, 100.33, 100.79 and 100.18% respectively, and for SIL were 99.27, 99.56, 99.83 and 99.44% respectively. The SRF values were approximating unity and showed high purity of the resolved peaks. The results were statistically compared with the HPLC reported method and no significant variance was discerned.

Keywords: Aspirin, Concurrent estimation, Sildenafil, UV-Spectrometric techniques.

INTRODUCTION

The combination of multiple drugs into single dosage form has become a common strategy in drug development. It improves patient docility and reduces production costs. ASP can be added to the therapy of erectile dysfunction, revealing a feasible therapeutic action, especially in patients at higher risk of cardiovascular diseases. Moreover, the utilization of low-dose aspirin and SIL may be useful in the handling of thin endometrium. In addition, sildenafil citrate can be added to low dose aspirin and low molecular weight heparin to improve fetal growth parameters in endangered pregnant women in uteroplacental blood flow in cases of high-risk pregnancy. The combining of ASP and SIL has demonstrated no pharmacokinetic interaction between them. Also, SIL has no effects on prothrombin or bleeding times in patients taking SIL alone or concurrently with ASP. Therefore, oral dispersible tablets of ASP and SIL were evolved by the direct compression method. ASP is chemically 2-(Acetyloxy)benzoic acid, has also been named as acetylsalicylic acid, Figure 1. Aspirin is widely used in low doses in preventing antiplatelet aggregations in patients at dicey of occlusive vascular events. Many analytical approaches have been announced for the definition of ASP like spectrophotometry, HPLC, RP-HPLC, UPLC, TLC, capillary
zone electrophoresis\textsuperscript{15} and raman spectroscopy\textsuperscript{16}. SIL is chemically 5-[2-Ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one dihydrogen 2-hydroxypropane-1,2,3-tricarboxylate, which belongs to phosphodiesterase inhibitors PDEs, specific type 5, Figure 1.\textsuperscript{8} It was initially synthesized to treat angina pectoris and hypertension. Then, a concomitant as penile erection was discovered and now it is long-established in the handling of erectile dysfunction\textsuperscript{17}. Also, SIL has FDA approval for the handling of pulmonary arterial hypertension\textsuperscript{18–22}. Various techniques were applied for SIL definition like spectrophotometric methods\textsuperscript{23,24}, HPLC\textsuperscript{25}, RP-HPLC\textsuperscript{26}, GC\textsuperscript{27,28}, capillary zone electrophoresis\textsuperscript{29}, X-ray fluorescence spectrometry\textsuperscript{30}. Literature review showed one UV-spectrometric technique for the concurrent estimation of ASP and SIL based on zero crossing first-derivative UV-spectrometry\textsuperscript{31}. Also, one HPLC method was announced for the concurrent determination of ASP and SIL\textsuperscript{3}. However, these previous studies have a low sensitivity in quantification, and have an important constraint on all results discussed in this area.

The target of this study is to evolve easy, rapid, and accurate approaches for the concurrent estimation of aspirin and sildenafil citrate. These spectral techniques are: ratio subtraction (RS) along with spectrum subtraction method (SS), absorption correction method (ACM), area under the curve correction method (AUCCM) and induced dual wavelength method (IDWM). Also, to ensure that ASP is free from its degradation product and to check the purity and similarity of SIL, the spectral ratio factor (SRF) was estimated. The advanced methods were verified in concurrence with International Conference on Harmonisation (ICH) criteria\textsuperscript{32}.

**MATERIALS AND METHODS**

**Devices and software**

The analysis was conducted on JASCO V-650, employing a pair of 1.0 cm quartz cells. Scans were executed at 200.0 to 400.0 nm. To homogenize the solutions an Ultrasonic bath model power sonic 405 (Korea) was employed. A SARTORIUS balance model 2474 (Germany) was adopted; with accuracy ± 0.1 mg. Calibrated volumetric flasks, whatman filter paper grade 91 and micropipettes were used.

**Fig. 1:** Structural formula of (a) ASP and (b) SIL.

**Chemicals**

Standard API of ASP and SIL were supplied by JQC (Huayin); China, Xuhuang; China, certified to have a purity of 99.8%, 99.5% respectively. Ethanol of analytical grade (Scharlau Chemie. S.A, Spain) was utilized. Aspirin® Bayer enteric-coated tablets; any tablet claimed to consist of 100 mg ASP and Vega® film-coated tablets; any tablet claimed to consist of SIL amounting to 50 mg base (Asia pharmaceutical industries, Syria) were purchased from a pharmacy. Sodium Starch Glycolate (Hzhou Zhewang, China), Cross Povidone (Shaanxi greenyo, China), Aerosil (Fengchen, China), Magnesium stearate (Peter Greven Asia SDN.BHD, Malaysia), Talc (euro Minerals, Austria) and Lactose (Shreeji pharma international, India) were used to prepare oral dispersible tablets\textsuperscript{7}.

**Preparation of standard solutions**

Stock solutions of 1000.0 μg/mL of ASP and SIL were prepared independently by dissolving 25.0 mg in 22.0 mL ethanol and sonicated for 8 min, then diluted the volume to 25.0 mL utilizing the same solvent. Working solutions were diluted from the stock solutions to get ASP and SIL at a concentration of 50.0 μg/mL for each.

**Laboratory synthetic mixtures preparation**

Five combinations including expected ratios of ASP and SIL were equipped into a set of 5 mL volumetric flasks from stock standard solutions using ethanol as a solvent. Moreover, pharmaceutical drug of ASP was mixed with specific concentration of SIL, and vice versa. This process was undertaking to demonstrate
that the excipients of either of these drugs did not interfere with each other.

Preparation of pharmaceutical products

10 tablets of ASP (100 mg/enteric-coated tablet) and 10 tablets of SIL (50 mg base/film coated tablet) were weighed and their average weight was calculated. Amounts equivalent to 25.0 mg ASP and 12.5 mg SIL were weighed, conveyed to 25.0 mL volumetric flask and dissolved in 22.0 mL ethanol, then sonicated for 8 min and diluted the volume with ethanol. A suitable amount filtered then 0.5 mL was withdrawn from the solution and conveyed into 5.0 mL volumetric flask, the volume was diluted with ethanol to get a final concentration of ASP and SIL equal to 100.0 μg/mL and 50.0 μg/mL, respectively. Oral dispersible tablet having label claim for ASP 150.0 mg and SIL 50.0 mg was designed in the laboratory. In the same way, a final concentration of (90.0 μg/mL ASP and 30.00 μg/mL SIL) were acquired.

RESULTS AND DISCUSSION

The absorption spectra of ASP and SIL in ethanol show partial overlap. The ratio of the two ingredients is (3:1) or (2:1) for ASP and SIL, respectively.

In their absorption spectra, it was observed that ASP shows two maximum absorption at 226 nm and 276 nm. Using $\lambda_{\text{max}}$ 276 nm enables us to determine both ingredients in the whole range of linearity. SIL has $\lambda_{\text{max}}$ at 294 nm. Many UV-spectrometric techniques were advanced over many years. The aim of this diversity in these methods is to get simple methods that achieve high sensitivity, accuracy and precision for assessing the ingredients in their pharmaceutical tablets. Zero order Spectral characteristics are disclosed in Figure 2.

Ratio subtraction method (RS)

This method is carried out when one ingredient is more prolonged than the other. It can determine the less continuous ingredient (ASP) in the binary combinations. This method is applied through three steps as follows:

- **Step 1:** (ASP+SIL) admixture is divided by a specific divisor SIL´ to get a new spectrum representing (ASP/SIL´+ constant).
- **Step 2:** This constant is canceled through subtraction.
- **Step 3:** The $D_0$ spectra of ASP is gained by multiplying SIL´ by the spectrum ASP/SIL´ which have got from the second step.

The constant was acquired from the spectrum $[(\text{ASP+SIL})/\text{SIL´}]$ in the region where the spectrum of SIL is more extended (300.0-320.0 nm) as disclosed in Figure 3. The ratio spectra of admixture is disclosed in Figure 4. To select the leading concentration divisor of SIL, average absolute difference study (AAD) was done. 40 μg/mL gave the slightest variance between recorded and postulated constants as disclosed in Table 1.

**Fig. 2:** $D_0$ spectra of ASP (30.0μg/mL), SIL (30.0μg/mL) and an admixture consisting of (15.0 μg/mL) of ASP and (15.0 μg/mL) of SIL.
Amir Alhaj Sakur and Zahraa Kayali.

Fig. 3: The constant value obtained by division the $D_0$ spectra of SIL (10.0-50.0 μg/mL) by the divisor spectra (40.0 μg/mL SIL).

Fig. 4: The ratio spectra of admixture gained by dividing this admixture (30.0 μg/mL ASP + 30.0 μg/mL SIL) by SIL (40.0 μg/mL) as a divisor.

Table 1: Selection the appropriate concentration divisor of SIL in RS method.

| Mix no. | 15 μg/mL | 25 μg/mL | 40 μg/mL |
|---------|----------|----------|----------|
|         | Post$^a$ | Rec$^b$  | Post$^a$ | Rec$^b$  | Post$^a$ | Rec$^b$  |
| 1       | 2.096    | 2.212    | 1.22     | 1.233    | 0.737    | 0.747    |
| 2       | 2.840    | 2.779    | 1.651    | 1.615    | 0.999    | 0.978    |
| 3       | 1.028    | 1.055    | 0.597    | 0.613    | 0.362    | 0.371    |
| 4       | 1.733    | 1.818    | 1.007    | 1.056    | 0.610    | 0.640    |
| 5       | 0.707    | 0.669    | 0.411    | 0.389    | 0.249    | 0.235    |
| AAD$^c$ | 0.065    | 0.028    | 0.017    |

The values represent the constant at the plateau region (300.0-320.0 nm) for SIL.

$^a$postulated value of constant.

$^b$recorded value of constant.

$^c$average absolute difference between recorded and postulated constant values.
Spectrum subtraction method (SS)
This method is based on direct subtraction of the D₀ spectra of ASP gained by RS method from the D₀ spectra of the binary combinations.

Spectral ratio factor (SRF)
This method is advanced to verify the purity and uniformity between two spectra of the same ingredient. It relies on measuring the absorbance at three wavelengths; two of them is λ₁ and λ₂ at both sides of λₘₐₓ. Then, the absorbance ratio \( A_1=(A_{\lambda_{\text{max}}} / A_{\lambda_{1}}) \) and \( A_2=(A_{\lambda_{\text{max}}} / A_{\lambda_{2}}) \) is calculated. SRF is assured by dividing \( (A_{\lambda_{1}}/ A_{\lambda_{2}}) \) of the sample by \( (A_{\lambda_{1}}/ A_{\lambda_{2}}) \) of the standard ingredient. For ASP, the absorbance was recorded at λₘₐₓ (276.0 nm), λ₁ (272.0 nm) and λ₂ (280 nm). For SIL, the absorbance was recorded at λₘₐₓ (294.0 nm), λ₁ (285.0 nm) and λ₂ (304.4 nm). The SRF values showed a high purity of the resolved peaks. It was predestined that there were no distinction in ASP spectrum, which ticked that there was no trace of salicylic acid; which has a spectral range of 295-350 nm. The variances appeared at the ends of the spectrum; which demonstrates the good results attained despite the percent error acquired by the variances in absorbance at the ends of the spectrum as disclosed in Figure 5 (a) and (b).

Absorption correction method (ACM)
This method was evolved to determine ASP and SIL concurrently. It was observed that SIL has an extensive peak with maximum absorption λₘₐₓ at 294 nm with no absorbance for ASP, but at this wavelength, interference was observed between ASP and SIL. So, wavelength at 305 nm was chosen for estimation of SIL which gives the best results in quantification without any absorbance and interference with ASP spectrum. SIL interferes with ASP at its λₘₐₓ 276 nm; So, the absorption factor was estimated for unadulterated SIL. The absorption of ASP estimation was done using the absorption factor of unadulterated SIL (A at 276/A at 305=0.823) concurring to the Eq. (1):

\[
A_{\text{ASP,276 nm}} = A_{\text{mix,276 nm}} \times \left( \frac{A_1}{A_2} \right) 
\]

Where; \( A_1/A_2 \) is the absorption factor of unadulterated SIL (Aₘᵢₓ,276 nm/Aₘᵢₓ,305 nm).

Standard curves were constructed for ASP and SIL between absorbances of D₀ spectra (ASP at 276 nm, SIL at 305 nm) and their concentrations in (μg/mL).

**Fig. 5:** (a) The variances between the standard and resolved spectrum for ASP (60.0μg/mL), (b) The variances between the standard and resolved spectrum for SIL (15.0 μg/mL).
Area under the curve correction method (AUCCM)

This method \(^{38,39}\) depends on AUC of its \(D_0\) spectra. To raise the sensibility of ACM; absorbance has been replaced by AUC. SIL shows some interference at the region 270–285 nm (\(\lambda_3–\lambda_2\)), while ASP does not show any interference at the region 304–310 nm (\(\lambda_3–\lambda_2\)). So SIL can be determined directly at 304–310 nm. AUC of ASP estimation was done using the AUC factor of unadulterated SIL (\(F_{\text{AUC}}=2.245\)) concurring to the Eq.(2):

\[
\text{AUC}_{\text{ASP}}(270–285\text{ nm}) = \text{AUC}_{\text{mix}}(270–285\text{ nm}) - \frac{\text{AUC}_{\text{mix}}(270–285\text{ nm})}{\text{AUC}_{\text{mix}}(304–310\text{ nm})} \text{AUC}_{\text{mix}}(304–310\text{ nm})
\]

Where; \(\text{AUC}_{\text{mix}}(1–2)/\text{AUC}_{\text{mix}}(3–4)\) is area under curve factor of unadulterated SIL [(\(\text{AUC}_{\text{SIL}}(270–285\text{ nm}) \div \text{AUC}_{\text{SIL}}(304–310\text{ nm})\)].

Standard curves were constructed for ASP and SIL by plotting AUC values for ASP at 270–285 nm and SIL at 304–310 nm versus their concentrations in (\(\mu\)g/mL).

**Induced dual wavelength method (IDWM)**

This method \(^{40}\) has been advanced over dual wavelength method. Various wavelengths were tested and it was observed that (280, 293 nm) and (294, 278 nm) are the best wavelengths in selectivity and sensitivity. To oust the vestige of SIL on ASP spectrum, the equality factor of unadulterated SIL was reckoned; \(F_{\text{eqSIL}}=(A_{\text{SIL}}\text{ at } 280\text{ nm} / A_{\text{SIL}}\text{ at } 293\text{ nm})=0.833\). In the same way, SIL can be estimated by reckoning the absorbance variances at 294 nm and 278 nm, \(F_{\text{eqASP}}=(A_{\text{ASP}}\text{ at } 294\text{ nm} / A_{\text{ASP}}\text{ at } 278\text{ nm})=0.095\).

Standard curve of ASP was constructed between the absorbance variance values of ASP at \(D_0\) spectra after multiplying by \(F_{\text{eqSIL}}\), \(\Delta A=A_{280\text{ nm}}- (A_{293\text{ nm}}*0.833)\) and their corresponding concentrations. Similarly, the standard curve of SIL was constructed between the absorbance variance values of SIL at \(D_0\) spectra after multiplying by \(F_{\text{eqASP}}\), \(\Delta A=A_{294\text{ nm}}- (A_{278\text{ nm}}*0.095)\) and their corresponding concentrations.

**Methods validation and statistical analysis**

The advanced approaches were verified in concurrence with ICH criteria \(^{32}\). Linearity of ASP and SIL was implemented by measuring six concentrations of ASP and SIL separately. Range of linearity for ASP and SIL is within 25-100 \(\mu\)g/mL and 10-50 \(\mu\)g/mL, respectively. All advanced approaches showed that correlation coefficient values are closer to 1 which gives good linearity as disclosed in table 2.

Limit of detection (LOD), limit of quantification (LOQ) were exposed as disclosed in Table 2.

Table 2: Validation parameters for ASP and SIL.

| Parameters | ASP | SIL |
|------------|-----|-----|
|            | RS  | ACM | AUCCM | IDW | SS  | ACM | AUCCM | IDW |
| Wavelength (nm) | 276 | 276 | 270 and 285 | 280 and 293 | 294 | 305 | 304 and 310 | 294 and 278 |
| N          | 6   | 6   | 6      | 6   | 6   | 6   | 6      | 6   |
| Linearity \((\mu\)g/mL\) | 25-100 | 25-100 | 25-100 | 25-100 | 10-50 | 10-50 | 10-50 | 10-50 |
| Intercept  | -0.0137 | -0.0137 | -0.198 | -0.0061 | -0.0157 | -0.0101 | -0.0488 | -0.0138 |
| Slope      | 0.0007 | 0.0007 | 0.0967 | 0.0057 | 0.0217 | 0.0195 | 0.1109 | 0.024 |
| Regression equation | Y=0.007x+0.0137 | Y=0.007x+0.0137 | Y=0.0967x+0.198 | Y=0.0057x+0.0061 | Y=0.0217x+0.0157 | Y=0.0195x+0.0101 | Y=0.1109x+0.0488 | Y=0.024x+0.0138 |
| Correlation coefficient | 0.9999 | 0.9999 | 0.9999 | 0.9999 | 0.9999 | 0.9999 | 0.9999 | 0.9999 |
| LOD \((\mu\)g/mL\) | 2.1433 | 2.1433 | 1.6838 | 1.6438 | 0.7801 | 0.8544 | 0.9224 | 0.8162 |
| LOQ \((\mu\)g/mL\) | 6.4948 | 6.4948 | 5.1026 | 4.9811 | 2.3640 | 2.5890 | 2.7951 | 2.4733 |
| System Suitability Testing\(\text{RSD}\%\)^{\text{a}} | 0.31 | 0.13 | 0.11 | 0.11 | 0.09 | 0.30 | 0.25 | 0.09 |
| Accuracy\(\text{Y}^\circ\) | 100.92±0.05 | 100.33±0.24 | 100.79±1.00 | 100.18±1.65 | 99.27±0.85 | 99.56±0.80 | 99.83±0.78 | 99.44±0.83 |
| Repeatability\(\text{RSD}\%\)^{\text{b}} | 0.88 | 1.05 | 0.92 | 0.97 | 1.24 | 1.15 | 1.24 | 1.20 |
| Intermediate precision\(\text{RSD}\%\)^{\text{c}} | 1.37 | 1.66 | 1.41 | 1.49 | 1.16 | 1.12 | 1.18 | 1.13 |

\(^{a}\)Average of six replicates of 80 \(\mu\)g/mL for ASP, and 40 \(\mu\)g/mL for SIL.

\(^{b}\)Average of three experiments.

\(^{c}\)Mean of the concentrations (30, 50, 70 \(\mu\)g/mL) for ASP, and (15, 25, 35 \(\mu\)g/mL) for SIL ± SD.

\(^{d}\)RSD% of the concentrations (40, 60, 80 \(\mu\)g/mL) for ASP, and (20, 30, 40 \(\mu\)g/mL) for SIL.
Accuracy of the advanced approaches was computed and expressed as the percentage recoveries and standard deviation (SD) of unadulterated ASP and SIL. Moreover, the approach of standard addition was implemented by adding known amounts of ASP and SIL at three various concentrations (80-100-120%). Results are disclosed in Table 3.

The precision of the advanced approaches was appreciated by analyzing three samples of ASP and SIL in triplicates on the same day (Intra-day or repeatability) and on three various successive days (Inter-days or intermediate precision). Acceptable and satisfying results RSD% were disclosed in Table 2.

System suitability testing was implemented by calculating RSD% for six replicated samples of ASP and SIL as disclosed in Table 2.

Specificity was executed by testing laboratory equipped admixtures consisting of diverse concentrations of ASP and SIL. The results were disclosed as mean recovery of all laboratory equipped admixtures (Recovery % ± SD) as displayed in Table 4.

Table 3: Standard addition method.

| Method | Level | Bayer®+Vega® | ODT |
|--------|-------|--------------|-----|
|        |       | ASP          | SIL | ASP          | SIL |
|        |       | Drug recovery%±SD | Drug recovery%±SD | Drug recovery%±SD | Drug recovery%±SD |
| ACM    | 80%   | 101.45±1.16 | 98.69±0.52 | 99.08±1.21 | 96.07±0.00 |
|        | 100%  | 101.30±0.53 | 99.37±0.20 | 101.94±1.96 | 96.87±0.71 |
|        | 120%  | 101.47±0.94 | 97.44±1.78 | 99.69±1.36 | 100.28±0.71 |
| AUCCM  | 80%   | 102.93±1.40 | 99.51±0.51 | 98.54±1.50 | 96.12±0.16 |
|        | 100%  | 102.52±0.31 | 99.71±0.25 | 101.29±1.46 | 97.71±0.94 |
|        | 120%  | 102.55±1.02 | 97.79±1.61 | 99.77±1.27 | 100.99±0.42 |
| IDW    | 80%   | 102.57±0.22 | 97.86±0.75 | 99.87±2.10 | 94.55±0.28 |
|        | 100%  | 101.40±0.65 | 98.66±0.58 | 101.45±0.81 | 96.93±1.22 |
|        | 120%  | 101.43±0.93 | 97.26±2.59 | 99.55±1.56 | 98.65±1.21 |

Table 4: Estimation of ASP and SIL in laboratory equipped combinations and tablet formulations.

| Mix ratio | ASP:SIL* (μg/mL) | Bayer®+Vega® | ODT |
|-----------|-----------------|--------------|-----|
|           | ASP             | SIL          | ASP             | SIL          |
|           | Drug recovery%±SD | Drug recovery%±SD | Drug recovery%±SD | Drug recovery%±SD |
| RS        | ACM            | AUCCM        | IDW           | SS          | ACM        | AUCCM        | IDW           |
| 1:1       | 30:30          | 103.03       | 97.70        | 97.80        | 96.29       | 99.24       | 99.73        | 99.93        | 99.55       |
| 2:1       | 80:40          | 102.39       | 101.24      | 102.19       | 99.76       | 97.70       | 97.06        | 96.80        | 98.00       |
| 3:1       | 100.86         | 99.52        | 99.52       | 99.33        | 99.65       | 98.95       | 99.04        | 98.85        |            |
| 4:1       | 101.43         | 100.88      | 100.81      | 101.53       | 102.25      | 101.08      | 101.81       | 101.28       |            |
| 6:1       | 101.28         | 101.85      | 100.67      | 101.05       | 100.78      | 99.41       | 99.28        | 99.54        |            |
| Meanb     | --             | 101.80      | 100.04      | 100.20       | 99.59       | 99.92       | 99.25        | 99.37        | 99.45       |
| SRF       | 0.9890         | --          | --          | --           | 1.0055      | --          | --           | --           |            |

Pharmaceutical Forms

| Mix ratio | Bayer®+Vega® | ODT |
|-----------|--------------|-----|
| 1:1       | 90:30        |     |
| 3.1* 90:30| 101.75       | 99.82 | 100.09 | 99.82 | 100.01 | 99.57 | 100.23 | 99.57 |
| 3:1 90:30 | 101.43       | 99.61 | 100.39 | 99.61 | 99.95 | 99.21 | 99.40 | 99.21 |
| Meand     | --           | 101.59 | 99.71 | 100.24 | 99.71 | 99.98 | 99.39 | 99.82 | 99.39 |
| SRF       | 0.9770       | --          | --          | --          | 1.0159 | --          | --          | --          |

*Average of three experiments.
*bAspirin Bayer® tablets and standard SIL.
*cVega® tablets and standard ASP.
*dAverage of the recovery of all laboratory equipped admixtures ± SD.
All advanced UV-spectrometric techniques were statistically compared with announced HPLC method. t and F values were reckoned to evaluate the differences in data for statistical significance. The results were judged to be less than the critical ones as disclosed in Table 5. Table 6 shows One-way ANOVA results gained by the advanced approaches and the one announced by HPLC. These results demonstrate that there was no considerable variance between the advanced methods and the announced one.

### Table 5: Statistical analysis of the advanced UV-spectrometric techniques and the announced HPLC method.

| Parameters | Bayer® + Vega® | ASP | SIL |
|------------|---------------|-----|-----|
| Mean       | 102.50        | 100.71 | 101.29 | 99.84 |
| SD         | 1.87          | 1.54  | 1.96  | 2.78  |
| Variance   | 3.50          | 2.38  | 3.84  | 7.71  |
| N          | 5             | 5     | 5     | 5     |
| t-test     | 0.41          | 1.29  | 0.64  | 1.51  |
| F-test     | 1.20          | 1.22  | 1.32  | 2.65  |
| SRF        | 0.9788        | --    | --    | 1.0112|

| Parameters | Bayer® + Vega® | ODT |
|------------|---------------|-----|
| Mean       | 101.41        | 100.41 |
| SD         | 1.42          | 1.59  |
| Variance   | 2.02          | 1.54  |
| N          | 5             | 5     |
| t-test     | 1.88          | 0.86  |
| F-test     | 1.64          | 1.31  |
| SRF        | 0.9900        | --    |

| Source of variation | Degree of freedom | Sum of squares | Mean Square | P value | F value | F critical |
|---------------------|-------------------|----------------|-------------|---------|---------|------------|
| ASP                 | Between columns   | 9              | 42.949      | 4.772   | 0.228   | 2.12       |
|                     | Within columns    | 40             | 137.950     | 3.449   | --      | --         |
|                     | Total             | 49             | 180.900     | --      | --      | --         |
| SIL                 | Between columns   | 9              | 9.412       | 1.046   | 0.763   | 2.12       |
|                     | Within columns    | 40             | 66.198      | 1.655   | --      | --         |
|                     | Total             | 49             | 75.611      | --      | --      | --         |

| Source of variation | Degree of freedom | Sum of squares | Mean Square | P value | F value | F critical |
|---------------------|-------------------|----------------|-------------|---------|---------|------------|

*Average of five experiments.
*Reported method is HPLC method.
*The tabulated value of Student’s t-test is 2.776 at p = 0.05.
*The tabulated value of F value is equal to 6.39 at p = 0.05.

### Table 6: Results of one-way ANOVA.

| Source of variation | Degree of freedom | Sum of squares | Mean Square | P value | F value | F critical |
|---------------------|-------------------|----------------|-------------|---------|---------|------------|
| ASP                 | Between columns   | 9              | 42.949      | 4.772   | 0.228   | 2.12       |
|                     | Within columns    | 40             | 137.950     | 3.449   | --      | --         |
|                     | Total             | 49             | 180.900     | --      | --      | --         |
| SIL                 | Between columns   | 9              | 9.412       | 1.046   | 0.763   | 2.12       |
|                     | Within columns    | 40             | 66.198      | 1.655   | --      | --         |
|                     | Total             | 49             | 75.611      | --      | --      | --         |

*There was no significance variance among these methods using one-way ANOVA at p < 0.05.
### Table 7: A comparative study between the advanced UV-spectrometric techniques used for simultaneous determination of ASP and SIL.

| Method                                    | Advantages                                                                 | Limitations                                                                 | LOD (μg/mL) |
|--------------------------------------------|----------------------------------------------------------------------------|-----------------------------------------------------------------------------|-------------|
| Ratio subtraction method (RS)              | Measured at zero order spectra. Ensured high accuracy and precision        | Only the less extended component can be determined                         | 2.1433 for ASP |
|                                           |                                                                            | Require three steps to obtain the recovered spectrum                        |             |
| Spectrum subtraction method (SS)           | Simple, uncomplicated method. Has only one step to get the zero order spectra | Applied as a supplementary method                                           | 0.7801 for SIL |
|                                           |                                                                            |                                                                            |             |
| Absorption correction method (ACM)         | Measured at zero order spectra                                             | Only applied when one of the two components has interference at λ_{max}     | 2.1433 for ASP |
|                                           |                                                                            | with the second component, while the second component has no interference  |             |
|                                           |                                                                            | with the first one at λ₂                                                    |             |
|                                           |                                                                            | Require for calculate absorption factor                                     |             |
| Area under the curve correction method (AUCCM) | Measured at zero order spectra. The sensitivity of this method is improved, compared to ACM, because the values obtained are always higher than the values obtained from the absorbances | One of the components of the binary mixture must have a free region         | 1.6838 for ASP |
|                                           |                                                                            | Require for calculate the AUC factor                                        | 0.9224 for SIL |
|  Induced dual wavelength method (IDWM)     | Measured at zero order spectra                                             | Require for calculate equality factor. Any aberration in these two selected wavelengths leads to artificial results | 1.6438 for ASP |
|                                           |                                                                            |                                                                            | 0.8162 for SIL |

### Conclusion

This work permits the concurrent estimation of ASP and SIL in binary synthetic admixtures and pharmaceutical formulations. All UV-spectrometric techniques used are uncomplicated, ecofriendly and economic. These approaches do not necessitate any sophisticated techniques, do not waste time and are easy to apply.

All proposed approaches showed similar accuracy, precision and sensitivity. In addition, RS and SS methods enable us to ascertain the purity of the resolved spectrum through the SRF technique; which is considered much simpler than the other methods have been used.

These results demonstrate the potential superiority of all proposed approaches over the UV announced one. Moreover, the solvent used in this technique (ethanol) is more environmentally friendly and more preferable than solvents used in literature review.

The evaluation of these methods included comparison between results of these studies and published HPLC work and no significant variance was discerned.

### REFERENCES

1. M. Žegarac, E. Lekšić, P. Šket, J. Plavec, M. D. Bogdanović, D. K. Bučar, et al., "A sildenafil cocrystal based on acetylsalicylic acid exhibits an enhanced intrinsic dissolution rate", *Cryst Eng Comm*, 16(1), 32-35 (2014).
2. M. Kunicki, K. Łukaszuk, I. Woclawek-Potocka, J. Liss, P. Kulwikowska and J. Szczyptańska, "Evaluation of granulocyte colony-stimulating factor effects on treatment-resistant thin endometrium in women undergoing in vitro fertilization", *Biomed Res Int*, 2014, 913235 (2014).
3. Y.Y. Hsieh, H.D. Tsai, C.C. Chang, H.Y. Lo and C.L. Chen, "Low-dose aspirin for infertile women with thin endometrium receiving intrauterine insemination: A prospective, randomized study", *J Assist Reprod Genet*, 17(3), 174-177 (2000).
4. R. D. Firouzabadi, R. Davar, F. Hojjat and M. Mahdavi, "Effect of sildenafil citrate on endometrial preparation and outcome
of frozen-thawed embryo transfer cycles: a randomized clinical trial", *Iran J Reprod Med*, 11(2), 151-158 (2003).
5. A.A.A. Mousa, M. A. Mohamed, M.S. Radwan and A.M. Sholkamy, "Effect of Sildenafil Citrate When Added to Low Molecular Weight Heparin and Small Dose Aspirin on Uteroplacental Perfusion in Cases of High-Risk Pregnancy", *Egypt J Hosp Med*, 75(5), 2934-2941 (2019).
6. M. D. Cheitlin, A. M. Hutter, R. G. Brindis, P. Ganz, S. Kaul, R.O. Russell, *et al.*, "Use of sildenafil (Viagra) in patients with cardiovascular disease", *J Am Coll Cardiol*, 33(1), 273-282 (1999).
7. A. Khristi, T. Soni and B. Suhagia, "Design Development &amp; In-Vitro Evaluation of Oral Rapid Mouth Dissolving Tablet Containing Sildenafil Aspirin Co-Crystals Using QbD Approach", *J Chem Pharm Res*, 8(10), 259-274 (2016).
8. British Pharmacopoeia commission, *British Pharmacopoeia*, 2016, I,1069 (2016).
9. Antitrombotic Trialistsˈ Collaboration, "Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients", *Bmj*, 324(7329), 71-86 (2002).
10. I. H. Refaat, "Application of multivariate calibration and derivative analysis in the spectrophotometric determination of some ascorbic acid pharmaceutical mixtures", *Bull Pharm Sci Assiut*, 27(2), 269-280 (2004).
11. F. A. El-Yazbi, O. A. Amin, E. I. El-Kimary, E. F. Khamis and S. E. Younis, "Simultaneous determination of methocarbamol and aspirin in presence of their pharmacopeial-related substances in combined tablets using novel HPLC-DAD method", *Drug Dev Ind Pharm*, 45(2), 265-272 (2019).
12. R. Vani and M. Sunitha, "Analytical Method Development and Validation for the Determination of Omeprazole and Aspirin Using Reverse Phase HPLC Method in Bulk and Dosage Form", *Univers J Pharm Res*, 2(4), 25-29 (2017).
13. E. F. Elkady, M. H. Tammann and A. A. El Maaty, "A comparative study of HPLC-UV and UPLC-DAD methods for simultaneous estimation of aspirin and ciletostal in the presence of their related impurities in bulk and capsules", *J Liq Chromatogr Relat Technol*, 40(4), 190-198 (2017).
14. A. A. Sakur, F. Mannaa and M. Y. Z. Eddin, "Preparing a New Chromatographic support from Local Syrian Clay and using it in Thin Layer Chromatography for Simultaneous Determination of Paracetamol, Caffeine and Aspirin in Tablets", *Res J Pharm Technol*, 14(4), 2119-2124 (2021).
15. S. Neuberger, K. Jooß, D. Flottmann, G. Scriba and C. Neusüß, "Raman spectroscopy and capillary zone electrophoresis for the analysis of degradation processes in commercial effervescent tablets containing acetylsalicylic acid and ascorbic acid", *J Pharm Biomed Anal*, 134, 122-129 (2017).
16. S. Adomavičiūtė, M. Velička and V. Šablinskas, "Detection of aspirin traces in blood by means of surface-enhanced Raman scattering spectroscopy", *J Raman Spectrosc*, 51(6), 919-931 (2020).
17. A. Dhaliwal and M. Gupta, "PDE5 inhibitor", *StatPearls* (2020). Last visit 29/7/2022.
18. S. Bhogal, O. Khraisha, M. Al Madani, J. Treece, S. J. Baumrucker and T. K. Paul, "Sildenafil for Pulmonary Arterial Hypertension", 26(4), e520-e526 (2019).
19. M. Humbert, H. A. Ghofrani, "The molecular targets of approved treatments for pulmonary arterial hypertension," *Thorax*, 71(1), 73-83 (2016).
20. D. A. Kass, E. Takimoto, T. Nagayama and H. C. Champion, "Phosphodiesterase regulation of nitric oxide signaling", *Cardiovasc Res*, 75(2), 303-314 (2007).
21. F. Murray, M. R. MacLean and N. J. Pyne, "Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension", *Br J Pharmacol*, 137(8), 1187-1194 (2002).
22. J. Nagendran, S. L. Archer, D. Soliman, V.
Gurtu, R. Moudgil, A. Haromy, et al., "Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility", *Circulation*, 116(3), 238-248 (2007).

23. A. A. Sakur and S. Affas, "Simple and Sensitive Spectrophotometric Determination of Sildenafil Citrate in Pharmaceutical Formulations", *Res J Pharm Technol*, 10(12), 4242-4246 (2017).

24. Y. M. Issa, W. F. El-Hawary, A. F. A. Youssef and A. R. Senosy, "Spectrophotometric determination of sildenafil citrate in pure form and in pharmaceutical formulation using some chromotropic acid azo dyes", *Spectrochim Acta Part A Mol Biomol Spectrosc*, 75(4), 1297-1303 (2010).

25. N. Daraghmeh, M. Al-Omari, A. A. Badwan and A. M. Y. Jaber, "Determinaton of sildenafil citrate and related substances in the commercial products and tablet dosage form using HPLC", *J Pharm Biomed Anal*, 25(3-4), 483-492 (2001).

26. B. Reddy and Y. R. Reddy, "Validation and stability indicating RP-HPLC method for the determination of sildenafil citrate in pharmaceutical formulations and human plasma", *E-Journal Chem*, 5(S2), 1117-1122 (2008).

27. Y. dong Jeong, S. Suh, J. Y. Kim, M. K. In and K. J. Paeng, "Simultaneous determination of sildenafil, tadalafl, and vardenafil in pharmaceutical preparations by high-temperature gas chromatography/mass spectrometry", *Chromatographia*, 79(23), 1671-1678 (2016).

28. C. N. Man, N. M. Nor, R. Lajis and G. L. Harn, "Identification of sildenafil, tadalafl and vardenafil by gas chromatography–mass spectrometry on short capillary column", *J Chromatogr A*, 1216(47), 8426-8430 (2009).

29. D. T. R. Vidal, M. A. Augelli and C. L. do Lago, "Determination of sildenafil and vardenafil by capillary zone electrophoresis using capacitively coupled contactless conductivity detection", *Anal Methods*, 5(8), 2041-2045 (2013).

30. R. S. Ortiz, K. C. Mariotti, N. V. Schwab, G. P. Sabin, W. F. C. Rocha, E. V. R. de Castro, et al., "Fingerprinting of sildenafil citrate and tadalafl tablets in pharmaceutical formulations via X-ray fluorescence (XRF) spectrometry", *J Pharm Biomed Anal*, 85, 7-11 (2012).

31. A. Khristi, R. Mardia and B. Suhagia, "UV Spectrophotometric Method Development and Validation of First Derivative Method for Simultaneous Estimation of Sildenafil Citrate (SIL) and Aspirin (ASP) in Bulk and Tablet Dosage Form", *Indo Am J Pharm*, 5(09)-2837-2843 (2015).

32. Q2B: "Guidance for Industry Q2B Validation of Analytical Procedures", *Methodology, International Conference on Harmonisation (ICH)*, (1996).

33. R. H. Obaydo and A. A. Sakur, "Fingerprint spectrophotometric methods for the determination of co-formulated otic solution of ciprofloxacin and fluocinolone acetonide in their challengeable ratio", *J Anal Methods Chem*, 2019, Article ID 8919345 (2019).

34. H. M. Lotfy and S. S. Saleh, "Testing the purity of spectral profiles: finger-print resolution of complex matrices and extraction of absorbance signals", *Spectrochim Acta Part A Mol Biomol Spectrosc*, 205, 160-169 (2018).

35. M. Dolores, E. A. Morales-Hipólito, J. A. Garduño-Rosas, A. Villaseñor and R. López-Arellano, "Development and validation of an alternate stability-indicating UV spectrophotometric analytical method for aspirin in tablets", *Indian J Pharm Sci*, 78(6), 810-817 (2017).

36. K. Attala and A. Elsonbaty, "Smart UV spectrophotometric methods based on simple mathematical filtration for the simultaneous determination of celecoxib and ramipril in their pharmaceutical mixtures with amlodipine: A comparative statistical study", *Spectrochim Acta Part A Mol Biomol Spectrosc*, 244, 118853 (2021).

37. C. V. Patela, A. P. Khandhar, A. D. Captain and K. T. Patel, "Validated
Absorption Factor Spectrophotometric and Reversed-Phase High-Performance Liquid Chromatographic Methods for the Determination of Ramipril and Olmesartan Medoxomil in Pharmaceutical Formulations Chintan", *Eurasian J Anal Chem* 2(3):159-171 (2007).

38. S. S. Saleh, H. Salem, H. M. Lotfy, N. Y. Hassan and M. B. El-Zeiny, "A Comparative study of different aspects of manipulating ratio spectra applied for ternary mixtures: derivative spectrophotometry versus wavelet transform", *Spectrochim Acta Part A Mol Biomol Spectrosc*, 135, 1002-1010 (2015).

39. H. M. Lotfy and S. S. Saleh, "Recent development in ultraviolet spectrophotometry through the last decade (2006-2016): A review", 8(10), 40-56 (2016).

40. H. M. Lotfy, D. A. Ahmed, M. K. Abdel Rahman and S. A. F. Weshahy, "Study of efficiency and spectral resolution for mathematical filtration technique using novel unlimited derivative ratio and classical univariate spectrophotometric methods for the multicomponent determination-stability analysis", *Heliyon*, 5(5), e01669 (2019).
تطوير أربع تقنيات طيفية للكشف عن الأقمشة فوق البنفسجية للتحديد المتجانس للأسبرين، وسيارات السيدينافيل في مزيجهما الثنائي وفي التركيبات الصيدلانية

أمير الحاج صقر* - زهراء كيالي
قسم الكيمياء التحليلية والغذائية، كلية الصيدلة، جامعة حلب، حلب، سوريا

اعتبر الجمع بين الأسبرين وسيارات السيدينافيل ضمن جريعة وحيدة موضوع اهتمام لفترة طويلة؛ وذلك بسبب التأثير التأريبي لعلاج العديد من الأمراض. لذلك، هناك حاجة ماسة لاستخدام تقنيات التحليل الطيفي في المجال فوق البنفسجي للتحديد المتجانس للأسبرين وسيارات السيدينافيل في مزيجهما الثنائي، وفي المستحضرات الصيدلانية. في هذه الورقة البحثية تم تطوير أربع تقنيات طيفية بسيطة ومنخفضة التكلفة ودقيقة من أجل التحديد المتجانس للأسبرين وسيارات السيدينافيل. تشمل الطرق المطورة عالياً طيف مجموعة المركبة الصفرية وذلك باستخدام طريقة الطرح النصبي جنبًا إلى جنب مع طريقة طرح الطيف، بطريقة تصنيف الامتصاصية، وطريقة المساحة تحت المنحنى المصمحة، وطريقة طول الموجة المزدوج المستحث. علاوة على ذلك، تم تطوير طريقة طيفية لتوفير التقاويا وذلك باستخدام معامل النسبة الطيفية؛ الذي يعتبر أول اختبار طبيعي تم استخدامه للتحقق من نقاوة الأسبرين في الأشكال الصيدلانية.

تراوحت خطيء جميع تقنيات ضمن المجال 0.25-400 ميكروجرام/مل للأسبرين، و0.05-8.000 ميكروجرام/مل لسيرات السيدينافيل. وكان متوسط النسبة المئوية لاسترداد للأسبرين 100.92 ± 10.79% و0.96% و99% لسيارات السيدينافيل على التوالي. كانت قيم معامل النسبة الطيفية قريبة من الواحد وأظهرت درجة نقاوة عالية للقسم التي تم استردادها. تم مقارنة النتائج إحصائياً مع طريقة الكروماتوجرافيا السائلة عالية الأماء المذكورة ولم يلاحظ أي فرق معياري بين النتائج.